The parathyroid hormone, PTH, is responsible for calcium and phosphate ion homeostasis in the body. The first 34 amino acids of the peptide maintain the biological activity of the hormone and is currently marketed for calcium imbalance disorders. Although several methods for the production of recombinant PTH(1-34) have been reported, most involve the use of cleavage conditions that result in a modified peptide or unfavorable side products. Herein, we detail the recombinant production of 15 N-enriched human parathyroid hormone, 15 N PTH(1-34), generated via a plasmid vector that gives reasonable yield, low-cost protease cleavage (leaving the native N-terminal serine in its amino form), and purification by affinity and size exclusion chromatography. We characterize the product by multidimensional, heteronuclear NMR, circular dichroism, and LC/MS.
Introduction
The human parathyroid hormone, PTH, and its paracrine acting counterpart, parathyroid hormone-related peptide, PTHrP, are the main hormones for regulating calcium and phosphate ions homeostasis in the human body [1, 2] . PTH is produced as a 115-residue prepropeptide, which undergoes cleavage by multiple proteases to yield the final 84-residue hormone that acts upon parathyroid receptors 1 and 2 [3, 4] . Cleavage studies have demonstrated that the first 34 amino acids of PTH retains the biological activity of the hormone [5] .
Efforts to produce recombinant PTH have been ongoing since the 1980s [6] [7] [8] [9] [10] [11] [12] [13] [14] , with the first report of full hormone production detailed in 1988 [6] . In general, recombinant production offers advantages over standard synthetic methodologies: fast cellular growth achieving high density using inexpensive substrates [15] , facile isotope enrichment, and post-translational modifications such as glycosylation. Several studies describing the recombinant production of PTH employing fusion tags subsequently cleaved using cyanogen bromide [11] , enterokinase [16] and/or factor X [14] have been reported. All of these cleavage methods are either relatively harsh or utilize expensive reagents. A most promising production reported by Oldenburg et al. [11] , showed the concatenation of PTH(1-34) cDNA in a vector that expressed robustly and allowed for the cleavage of PTH fragments by cyanogen bromide. Although this method produced the desired peptide in high yield (>300 mg/l), both native methionine residues (M8 and M18) were mutated to Leu to prevent their conversion to homoserine upon CNBr cleavage. In addition, to cleave each PTH peptide following isolation, a C-terminal methionine was cloned into the construct, resulting in a C-terminal homoserine residue post cleavage. In light of the critical roles of the N-terminal residue of PTH in receptor activation [5] and of the native methionine residues in receptor binding [17] , it is desirable to develop an expression method that gives reasonable yields with the native sequence of PTH. Equally desirable would be to find a cleavage method that is mild and not requiring expensive reagents.
To address these issues, we report our efforts to generate 15 N-labeled PTH(1-34) with the amino terminus as a free base in a constructed plasmid vector, pJCC04a-a modified pET32b vector containing a thioredoxin fusion tag upstream of a tobacco etch virus (TEV) protease cleavage site. We believe this production method (Figure 1 ) to be more versatile and economical than currently reported methods particularly because TEV protease can be freely generated recombinantly and cleaves over a wide range of amino acid residues following glutamine in its recognition sequence.
Materials and Methods

Design of pJCC04a Plasmid Vector
To generate the pJCC04a vector, the QuikChange site-directed mutagenesis kit (Stratagene) was used to insert a BamHI site downstream from the coding sequence for the N-terminal Thioredoxin (TrxA) and 6x-His purification tag in the pET32b vector (Novagen) using the following oligonucleotides (Integrated DNA Technologies):
To introduce the coding sequence for a TEV protease cleavage recognition site and a multiple cloning site, a synthetic insert was designed using the following 5 0 -phosphorylated oligonucleotides (Integrated DNA Technologies)
These oligonucleotides were mixed (50 mM each), heated to 95 C for 5 min, slowly annealed by shifting the temperature to 70 C over 30 min, then rapidly cooled to 25 C using a thermocycler. The modified pET32b plasmid was digested with BamHI and NotI, and the synthetic insert was ligated using Quick T4 DNA ligase (New England BioLabs, Ipswich, MA, USA). The resulting vector was confirmed by DNA sequencing at the Dartmouth Core Sequencing facility.
Expression and Purification of 15 N-PTH(1-34)
Parathyroid hormone (1-34) cDNA was incorporated into pJCC04a cloning site via site directed mutagenesis according to QuikChange Lightning protocol (Stratagene (La Jolla, CA, USA)) using the following cDNA primer (Integrated DNA Technologies, IA, USA (Coralville, IA, USA))
The underlined sequences are the complementary strand overhangs for pJCC04a vector.
Escherichia coli strain BL21 Star (DE3) (Invitrogen), transformed with the aforementioned pJCC04a plasmid containing the PTH (1-34) cDNA, was grown in Terrific Broth (TB) at 37 C with shaking at 220 rpm until the optical density of the culture at 600 nm was approximately 4. The culture was then centrifuged slowly at 1500 rpm for 20 min and the supernatant discarded. The residual pellet, for 15 N-enriched growth, was resuspended in minimal media (48 mM Na 2 HPO 4 , 22 mM KH 2 PO 4 , 9 mM NaCl, 5 mM MgSO 4 , 0.2 mM CaCl 2 , 0.25Â trace metals solution [29] , 21 mM Na 2 MoO 4 .2H 2 O, 0.25Â BME Vitamins (Sigma, 100Â stock), 1 mg/ml Thiamine, 10 g/l dextrose (Fisher Scientific), 3 g/l 15 N NH 4 Cl (Cambridge Isotope Laboratories), pH 8.0). The resulting suspension was grown at 37 C for 1 h before inducing peptide overexpression with 2.5 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) in the presence of 1 mM MgSO 4 and 1 ml ultrapure glycerol. The cells were then grown at 20 C for 16-18 h and then centrifuged at 4000 rpm for 30 min. Pelleted cells were subsequently resuspended into 50 ml lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0) containing 1 tablet of EDTA-free protease inhibitor cocktail (Roche), 2 ml benzonase (250 U/ml, Sigma-Aldrich), 2 mM MgCl 2 , and 1 ml ultrapure glycerol. The resulting suspension was lysed by French press at 15,000 psi.
A total of 8 M urea was added to the cell lysate and stirred at room temperature for 18-20 h before pelleting at 40,000 rpm for 40 min. On an Amersham Biosciences AKTAxpress fast protein liquid chromatography instrument, a 5 ml Histrap TM HP nickel affinity column (GE Healthcare, Buckinghamshire, UK) was equilibrated with loading buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM Imidazole, pH 8.0), and the supernatant from the urea prep was directly loaded onto it, followed by a 10-column volume wash with loading buffer. A gradual gradient elution (buffer: 50 mM NaH 2 PO 4 , 300 mM NaCl, 500 mM Imidazole, pH 8.0) was used to elute TrxA- 15 N PTH(1-34) fusion protein off the nickel affinity column. Protein elution was monitored by UV light at 280 nm. The fractions obtained were assessed by SDS-PAGE, with the cleanest fractions pooled and subsequently subjected to 16 h overnight TEV protease digestion via dialysis into 50 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, and 10% glycerol at 4 C (1 : 10 ratio of protease to protein). The resulting mixture was loaded on a 5 ml HisTrap TM (GE healthcare, Buckinghamshire, UK) affinity column to remove the TEV protease and thioredoxin proteins. SDS-PAGE analysis was conducted on a 16% Tricine peptide gel (Invitrogen (Carlsbad, CA, USA)). Fractions containing the peptide alone, and with trace TrxA, were pooled, concentrated, and loaded onto a GE © HiLoad Superdex75 16/60 size exclusion column. dH 2 O, pH 3.1 was used to separate the peptide from the TrxA. The purest fractions of 15 N PTH(1-34) were pooled, and the concentration was determined by UV absorbance at 280 nm before storage at À80 C. All UV readings for peptide concentration were carried out on a Beckman Coulter (Danvers, MA, USA) DU800 spectrophotometer. Before further analysis, peptide solutions were lyophilized and reconstituted in the appropriate buffer and as needed, further concentrated (3.5 kDal MWCO centrifugal concentrator; Vivaspin, Sartorius Stedim Biosciences). Unlabeled, synthetically derived PTH (1-34) was purchased from the Tufts University Core Facility. 
Circular Dichroism Analysis
Circular dichroism experiments were conducted on a Jasco, Inc (Easton, MD, USA) J-815 Spectrometer (cell path length 0.1 cm) on a 52 mM sample of 15 N PTH(1-34) peptide in dH 2 O, pH 3.1. The absorbance was converted to residue molar ellipticity (y) using standard conversion equation [18] , and the percent helicity was calculated as previously described [19] .
Liquid Chromatography and Mass Spectrometry (LC/MS)
LC/MS analysis was run on a Shimadzu LCMS-8030 Tandem Quadrupole LC/MS/MS instrument with a detection limit of 2000 m/z. Methanol/dH 2 O (0.1%, TFA) were used as the eluting solvents. A gradient elution was employed with a flow rate of 8.4 ml/min with monitoring at wavelengths of 190-800 nm. Ionization was obtained by electrospray (ESI) with a DL temperature of 250 C and a heat block temperature of 400 C. The column oven was set to 40-90 C.
Both positive and negative ions were monitored. A Savitzky-Golay processing method was employed to smooth the data [20] .
NMR Characterization
All NMR experiments were acquired on a Bruker 700 MHz spectrometer equipped with a cryoprobe and pulse field gradients. Data acquisition and processing were performed with Topspin software (version 3.2; Bruker) running on a Linux workstation. All experiments were run at 298 K. One-dimensional 1 H NMR, with a total of 128 scans, were acquired for each experiment with labeled (85 mM) and unlabeled (1 mM) PTH (1-34) TEV CLEAVED PTH(1-34)
Results pJCC04a Plasmid Vector Design
The pJCC04a plasmid is modified from pET32b and contains the ampicillin resistance gene and a thioredoxin tag. Our modifications introduced the coding sequence for a TEV protease cleavage recognition site downstream from the 6xHis tag sequence, as well as a multiple cloning site containing the sequences for BamHI, NcoI, and XhoI restriction endonucleases. The full recombinant vector plasmid (native and with PTH insert) is shown in Figure 2 .
Peptide Expression and Purification
The expression of PTH(1-34) yielded approximately 20 mg per liter of minimal media, with greater than 95% purity as determined by LC/MS. The pJCC04a vector was induced for protein production using IPTG (Figure 3) . The thioredoxin fusion tag on the plasmid vector allowed for robust expression, although, as previously reported [21] , the generated fusion protein, TrxA-15 N PTH(1-34), was insoluble following cell lysis. To recover the protein, the cell pellet was resuspended using the urea solubilizing preparation described in Materials and Methods. The fusion protein, washed with excess loading buffer to remove residual urea, was purified to homogeneity using a gradient elution on Ni 2+ affinity column (Figure 4) . The incorporation of the TEV protease cleavage site allowed for the generation of untagged peptide following TEV digestion and is visible on SDS-PAGE analysis [ Figure 5(a) ]. Attempts to isolate the peptide from thioredoxin and TEV post-digestion by Ni 2+ affinity column resulted in most of the protein eluting during the imidazole gradient [ Figure 5(b) ]. This is likely because of non-specific interactions of the peptide with the Ni 2+ column. Nonetheless, the peptide (~4 kDa) was readily separated from residual thioredoxin protein (15 kDa) by size exclusion chromatography (Figure 6 ). 
Peptide Composition and Structure
An al iquot of generated 15 N PTH(1-34) peptide was lyophilized and subjected to LC/MS for analysis ( Figure 7 ). This showed a peptide composition of 98% purity eluting at 6.5 min over a gradient elution of methanol/water (0.1 % TFA). The molecular weight of the The secondary structure of 15 N PTH(1-34) was assessed by circular dichroism spectroscopy (Figure 8 ), which revealed that the hormone is primarily random coil with 28 % helical content, in accord with previous observations [22] [23] [24] .
Comparison of the 1D 1 H spectrum of this sample with synthetically derived, unlabeled PTH(1-34) revealed an identical number of peaks [ Figure 9 (a)] that were readily superimposable. . The sequence assignment could be easily deduced from those reported in similar conditions [25] .
Discussion
The production method described here yields the biologically active, N-terminal fragment of PTH utilizing proteolytic cleavage by a recombinantly expressed and relatively common TEV protease. We utilize pJCC04a-a pET32b vector plasmid containing a thioredoxin fusion protein, which is reported to facilitate expression of short peptides otherwise not expressed [26] , a TEV protease cleavage recognition site, and multi-endonuclease sites for BamHI, NcoI, and XhoI [ Figure 2(a) ]. A similar technique was recently reported for the production of the third intracellular loop of the vasopressin receptor [27] .
In our case, the desired PTH(1-34) peptide cDNA was readily inserted downstream of these modifications using long primer site directed mutagenesis [ Figure 2(b) ]. Our routine production and analysis show that we are able to attain reasonable yields (approx. 20 mg peptide per 1 l minimal media) of 15 N PTH(1-34) peptide with high purity, as confirmed by LC/MS. It is commonly thought that PTH is mostly random coil with transient helical character [22] at the N-termini and C-termini. Our analysis by CD corroborates this finding, revealing a small absorption at 222 nm corresponding to 28 % helical character. The 1 H NMR spectrum of our recombinant peptide is identical to that of synthetically derived peptide [ Figure 9 (a)]. Recombinant production allows for the facile incorporation of isotopic labels necessary for biophysical characterization by multidimensional NMR-a useful tool in assessing binding interactions with the class B G-protein coupled receptor responsible for the cellular responses of the hormone.
The recombinant production method described in this report is particularly suited for generating peptides hormones, such as PTH, whose biological activity is dependent on having its N-terminal residue as a free amine. In the case of a peptide containing multiple cysteines, we have found that purification in the presence of a reducing agent improves yields. The TEV protease cleanly and specifically cleaves after Gln of the following recognition sequence: ENLYFQX, where X can be any amino acid other than Pro [28] . Indeed, this versatility is one of the advantages of using TEV as a protease. Given these benefits, we believe that this vector and production methodology represent a generally applicable tool for the generation of recombinant peptides. 
